Recomendaciones preventivas cardiovasculares

Galán, Antonio Maiques; Cuixart, Carlos Brotons; Álvarez, Fernando; Pérez, Jorge Navarro; Lobos-Bejarano, José María; Sánchez-Pinilla, Ricardo Ortega; Rioboó, Enrique Martín; Banegas, José R.; Orozco‐Beltrán, Domingo; Guillén, Vicente Gil

doi:10.1016/s0212-6567(12)70010-0

Cited by 40 publications

(6 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, multiple therapeutic tools of proven efficacy exist to control the main CVRF, as well as guidelines and protocols endorsed by the main scientific societies [5]–[7,19]. …”

Section: Discussionmentioning

confidence: 99%

“…The IHD patient care protocol of the SVMFiC (2010 update) is used [19], available via the Abucasis intranet. The criteria used to define good control of the variables (Table 1) are those of the Cardiovascular Disease Prevention Group of the Preventive Activity and Health Promotion Program (PAPPS) [5]. …”

Section: Methodsmentioning

confidence: 99%

“…In Spain, ischemic heart disease (IHD) causes most CVD deaths (30% overall; 37% in men and 24% in women). The hospital morbidity rate for IHD was 317 per 100,000 inhabitants (447 in men and 189 in women) [3]–[5]. …”

Section: Introductionmentioning

confidence: 99%

“…In addition, much evidence now exists concerning pharmacological treatment aimed at the associated risk factors [5]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness of a new health care organization model in primary care for chronic cardiovascular disease patients based on a multifactorial intervention: the PROPRESE randomized controlled trial

Orozco-Beltrán

Ruescas-Escolano

Navarro-Palazón

et al. 2013

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundTo evaluate the effectiveness of a new multifactorial intervention to improve health care for chronic ischemic heart disease patients in primary care. The strategy has two components: a) organizational for the patient/professional relationship and b) training for professionals.Methods/designExperimental study. Randomized clinical trial. Follow-up period: one year. Study setting: primary care, multicenter (15 health centers). For the intervention group 15 health centers are selected from those participating in ESCARVAL study. Once the center agreed to participate patients are randomly selected from the total amount of patients with ischemic heart disease registered in the electronic health records. For the control group a random sample of patients with ischemic heart disease is selected from all 72 health centers electronic records.Intervention components: a) Organizational intervention on the patient/professional relationship. Centered on the Chronic Care Model, the Stanford Expert Patient Program and the Kaiser Permanente model: Teamwork, informed and active patient, decision making shared with the patient, recommendations based on clinical guidelines, single electronic medical history per patient that allows the use of indicators for risk monitoring and stratification. b) Formative strategy for professionals: 4 face-to-face training workshops (one every 3 months), monthly update clinical sessions, online tutorial by a cardiologist, availability through the intranet of the action protocol and related documents.Measurements: Blood pressure, blood glucose, HbA1c, lipid profile and smoking. Frequent health care visits. Number of hospitalizations related to vascular disease. Therapeutic compliance. Drug use.DiscussionThis study aims to evaluate the efficacy of a multifactorial intervention strategy involving patients with ischemic heart disease for the improvement of the degree of control of the cardiovascular risk factors and of the quality of life, number of visits, and number of hospitalizations.Trial registrationNCT01826929

show abstract

“…Nowadays, multiple therapeutic tools of proven efficacy exist to control the main CVRF, as well as guidelines and protocols endorsed by the main scientific societies [5]–[7,19]. …”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…In addition, much evidence now exists concerning pharmacological treatment aimed at the associated risk factors [5]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of a new health care organization model in primary care for chronic cardiovascular disease patients based on a multifactorial intervention: the PROPRESE randomized controlled trial

Orozco-Beltrán

Ruescas-Escolano

Navarro-Palazón

et al. 2013

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…A la hora de planificar un tratamiento no farmacológico para la obesidad hay que tener en cuenta un aumento en la actividad física, terapia conductual y por supuesto la dieta, siendo la combinación de todos ellos lo que mejores resultados ofrece [5][6][7] . Y aunque a día de hoy no existe consenso sobre qué terapia nutricional es la ideal para corregir este problema, diversos estudios 8,9 apoyan que la dieta hipocalórica, especialmente la Dieta Mediterránea (DM) hipocalórica 10,11 , es el tratamiento de elección a la hora de tratar la obesidad y el síndrome metabólico.…”

Section: Introductionunclassified